Collecting data for bladder cancer patients
Flemish Prospective Clinical and Pathological Database for Urothelial Cancer
Universitaire Ziekenhuizen KU Leuven · NCT03973671
This study is collecting information from bladder cancer patients to help improve future treatments and understand how the disease behaves.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Universitaire Ziekenhuizen KU Leuven (other) |
| Locations | 1 site (Leuven, Vlaams-Brabant) |
| Trial ID | NCT03973671 on ClinicalTrials.gov |
What this trial studies
This study aims to create a comprehensive databank for patients diagnosed with urothelial cancer by collecting demographic, clinical, pathological, and follow-up data. Patients will provide informed consent for their data to be used in future research, which will help validate existing nomograms for predicting cancer recurrence and progression. The data collection will utilize electronic case report forms developed in accordance with established guidelines. This initiative is expected to enhance the understanding and management of bladder cancer treatment.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18-90 who are undergoing various surgical procedures for bladder cancer.
Not a fit: Patients who do not consent to data collection or refuse the planned treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve risk stratification and treatment outcomes for bladder cancer patients.
How similar studies have performed: Other studies have successfully utilized similar databank approaches to enhance cancer treatment and management, indicating a promising avenue for this research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * who are aged between 18-90, * who are of male or female sex, * who give their informed consent to collect their clinical and pathological data, * who are planned to undergo TURBT for BC, * who are planned to undergo (salvage) radical cystectomy with or without an extended pelvic lymph node dissection, * who are planned to undergo tumor biopsy (from primary or metastatic tumor), * who are planned to undergo radical nephroureterectomy ± partial cystectomy or segmental ureterectomy, with or without a lymph node dissection, * who are planned to undergo endoscopic tumor biopsy or resection, * from whom metastases will be surgically removed. Exclusion Criteria: * patients who do not give their informed consent to collect their clinical and pathological data, * patients who withdraw their informed consent to use their clinical and pathological data, * patients who refuse the planned treatment, * women who are pregnant or have suspicion of pregnancy.
Where this trial is running
Leuven, Vlaams-Brabant
- University Hospitals Leuven — Leuven, Vlaams-Brabant, Belgium (RECRUITING)
Study contacts
- Principal investigator: Steven Joniau, MD, PhD — Assistant Professor
- Study coordinator: Murat Akand, MD
- Email: murat.akand@uzleuven.be
- Phone: +3216346687
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Urinary Bladder Neoplasms, Risk stratification, Recurrence, Progression, Non-muscle-invasive bladder cancer, Muscle-invasive bladder cancer